Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	35.85B
Revenue (ttm)	6.51B
Net Income (ttm)	335.54M
Shares Out	855.14M
EPS (ttm)	0.39
PE Ratio	115.21
Forward PE	39.99
Dividend	0.30 (0.67%)
Ex-Dividend Date	Jul 12, 2024

Volume	7,946,721
Average Volume	8,628,026
Open	44.47
Previous Close	45.97
Day's Range	44.47 - 46.11
52-Week Range	42.86 - 82.79
Beta	0.84
RSI	39.61
Earnings Date	Apr 28, 2025

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,185
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.